ProfileGDS5678 / 1433451_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 77% 77% 74% 77% 81% 82% 77% 81% 77% 77% 76% 77% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4084579
GSM967853U87-EV human glioblastoma xenograft - Control 25.3396677
GSM967854U87-EV human glioblastoma xenograft - Control 35.2965277
GSM967855U87-EV human glioblastoma xenograft - Control 44.9930574
GSM967856U87-EV human glioblastoma xenograft - Control 55.2419177
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5438981
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.839782
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2730977
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8470181
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2244577
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2370777
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2018576
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2791177
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2235177